RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of generating multiple cellular therapy products from a single source of iPSCs.

In this interview, we speak to Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease.

The study highlights the therapeutic success of Qihan’s off-the-shelf, dual-targeting iPSC-derived CAR-NK cell product, QN-139b, in treating refractory systemic sclerosis (SSc).

TheInduced Pluripotent Stem Cell (iPSC) Industry Trends & Forecasts 2025-2030: From Disease Modeling to Cell Therapy - iPSCs Emerge as Cornerstone of Precision Healthcare - ResearchAndMarkets.com ...

Cellistic reveals groundbreaking iPSC-based platforms to accelerate off-the-shelf allogeneic cell therapy development and manufacturing.

This article from ACROBiosystems explores the scalable manufacturing of iPSC-derived cell therapies via GMP-grade laminin.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to ...

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting Next-generation Engineering ...

Establishing cell lines to improve iPSC research The Jackson Laboratory has established and characterized a stable iPSC line, KOLF2.1J, to act as a high-quality baseline platform for modeling ...

--IN8bio, Inc., a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new positive preclinical data from its induced pluripotent ...

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms.